Ocular Therapeutix, Inc.
OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.24
Price+0.87%
$0.08
1Y
Price
Market Cap
$2.023b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-853.6%
EBITDA Margin-821.6%
Net Profit Margin-655.1%
Free Cash Flow Margin-853.6%
EBITDA Margin-821.6%
Net Profit Margin-655.1%
Free Cash Flow MarginRevenue
$52.038m
+0.4%
1y CAGR-3.1%
3y CAGR+1.1%
5y CAGREarnings
-$290.498m
-9.2%
1y CAGR-62.1%
3y CAGR-50.0%
5y CAGREPS
-$1.46
-2.8%
1y CAGR-12.9%
3y CAGR-11.0%
5y CAGRBook Value
$581.574m
$732.529m
Assets$150.955m
Liabilities$79.462m
DebtDebt to Assets
10.9%
-0.3x
Debt to EBITDAFree Cash Flow
-$240.944m
-11.1%
1y CAGR-49.6%
3y CAGR-42.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company